source
- FDA’s push to publish complete response letters faces legal uncertainty and possible pauseThe FDA began releasing complete response letters (CRLs) to the public last year, a move promoted as increasing transparency for drug developers, investors, and patients. However, the policy has e…
- UK biotech venture capital funding hits record high in Q2 2026, surpassing any full year since 2022UK biotech companies secured more venture capital in the second quarter of 2026 than they did in any full calendar year since 2022. The surge reflects a broader fundraising revival, with investors…